EFEMP2 and endometrioid adenocarcinoma: Our study found that high expression of EFEMP2 was associated with low differentiation of ovarian cancer, advanced clinical stage, and positive lymph node metastasis, but not with the tissue type of ovarian cancer (including serous cystadenocarcinoma, mucinous cystadenocarcinoma, and endometrioid carcinoma), and that EFEMP2 was highly expressed in ovarian cancer cells with high migration and invasion capacity [13].